Stereotactic ablative radiotherapy and surgery: two gold standards for early-stage non-small cell lung cancer?

Hanbo Chen; Alexander V Louie

doi:10.3978/j.issn.2305-5839.2015.05.08

Stereotactic ablative radiotherapy and surgery: two gold standards for early-stage non-small cell lung cancer?

Ann Transl Med. 2015 Jun;3(9):113. doi: 10.3978/j.issn.2305-5839.2015.05.08.

Authors

Hanbo Chen¹, Alexander V Louie¹

Affiliation

¹ Department of Radiation Oncology, London Regional Cancer Program, Western University, London, ON, Canada.

PMID: 26207241
PMCID: PMC4481359
DOI: 10.3978/j.issn.2305-5839.2015.05.08

Abstract

There is growing clinical equipoise between surgery and stereotactic ablative radiotherapy (SABR) in the management of early-stage non-small cell lung cancer (ES-NSCLC). Increasing evidence suggest similar outcomes between these modalities. Through the guidance of a multidisciplinary team, a shared decision making approach in this setting in favoured.

Keywords: Carcinoma; comparative effectiveness research; non-small cell lung; radiosurgery; retrospective studies; thoracic surgical procedures.